Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia

A technology of cannabinoid receptors and agonists, applied in the direction of drug combinations, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve the problems of membrane lipid peroxidation, non-description, damage, etc.

Inactive Publication Date: 2009-07-22
纽若科伊公司
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] 2. Reperfusion following cerebral ischemia leads to the generation of free radicals, which trigger peroxidation and damage of membrane lipids [18]
[0017] Cannabinoid-containing drugs have been administered to humans for the treatment of pain, however, there are no reports describing the observation of significant hypothermia in humans during such treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
  • Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia
  • Use of cannabinoid receptor agonists as hypothermia inducing drugs for the treatment of ischemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0203] Example 1 - Cardiac arrest

[0204] A 57-year-old woman was admitted to the hospital 21 minutes after collapsing without symptoms. Medical staff in the emergency room are on standby. The patient was evaluated in the emergency department, where the attending physician decided that the patient should be treated with hypothermia immediately to minimize the risk of damage to the brain and other tissues. An intravenous bolus injection of HU-210 (eg, 100 micrograms / kg body weight) or delta-8-THC phosphate administration (eg, 40 mg / kg body weight) is given.

[0205] The goal of hypothermia therapy is to lower the patient's core body temperature to 32-34°C for 12 to 24 hours (currently recommended by the American Heart Association). Depending on individual response to drug therapy, 1-4 additional IV bolus injections may be required (HU-210: additional injection of 20-100 μg / kg body weight; delta-8-THC phosphate: additional injection of 8-40 mg / kg body weight ). Additional b...

Embodiment 2

[0207] Example 2 - Perinatal asphyxia

[0208] A baby suffers from cerebral ischemia during labor because the umbilical cord is wrapped around its neck. The APGAR score 10 minutes after delivery was 6. The pediatrician decided that the patient should be treated with hypothermia immediately to minimize the risk of damage to the brain and other tissues. An intravenous bolus injection of HU-210 (eg, 100 micrograms / kg body weight) or delta-8-THC phosphate (eg, 40 mg / kg body weight) is given. Additional bolus injections may be given 6-12 hours after the first bolus injection.

[0209] The goal of hypothermia therapy is to lower the patient's core body temperature to 32-34°C for 12 to 24 hours (currently recommended by the American Heart Association). Depending on individual response to drug therapy, 1-4 additional IV bolus injections may be required (HU-210: additional injection of 20-100 μg / kg body weight; delta-8-THC phosphate: additional injection of 8-40 mg / kg body weight )...

Embodiment 3

[0211] Example 3 - Stroke

[0212] A 72-year-old patient was brought to the hospital 1 hour and 30 minutes after experiencing numbness and weakness throughout the right side of the body while walking. The patient was evaluated in neurology, and the attending physician suspected a stroke and decided that the patient should be immediately treated with hypothermia to reduce damage to the brain. An intravenous bolus injection of HU-210 (eg, 100 micrograms / kg body weight) or delta-8-THC phosphate (eg, 40 mg / kg body weight) is given.

[0213] The goal of hypothermia therapy is to lower the patient's core body temperature to 32-34°C for 12 to 24 hours (currently recommended by the American Heart Association). Depending on individual response to drug therapy, 1-4 additional IV bolus injections may be required (HU-210: additional injection of 20-100 μg / kg body weight; delta-8-THC phosphate: additional injection of 8-40 mg / kg body weight ). Additional bolus injections may be given 6-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of a cannabinoid receptor agonist for use in induction of hypothermia in a human being for the prophylaxis and treatment of ischemia.

Description

technical field [0001] The present invention relates to the use of compounds for inducing hypothermia in the prevention and treatment of ischemia. Ischemia refers to a lack of oxygenated blood flow to various body parts and can be caused by stroke, cardiac arrest and asphyxiation. Background technique [0002] Ischemia is the lack of oxygenated blood flow to various body parts and organs. Cerebral ischemia is an ischemic condition in which the brain or part of the brain does not receive sufficient blood flow to maintain normal neurological function. Cerebral ischemia can be the result of various serious diseases such as stroke or cardiac arrest, or of blocked arteries such as strangulation. Severe or prolonged brain ischemia can result in loss of consciousness, brain damage, or death. [0003] The neuroprotective effect of hypothermia induced after or during cerebral ischemia is evident in experimental animal stroke models [1-11]. In humans, two trials in cardiac arrest ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/538A61K31/16A61K31/454A61K45/06A61P9/10
Inventor 尤诺·雅格布·韦伯雅各布·高特弗瑞德森
Owner 纽若科伊公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com